C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer
Retrieved on:
Tuesday, June 20, 2023
Michael G. DeGroote School of Medicine, Drug development, Therapy, Research, CCCC, Bladder cancer, Genentech, Chemistry, National Cancer Institute, Queen Elizabeth, McMaster University, Patient, Queen Elizabeth II Health Sciences Centre, Astellas Pharma, Sanofi, FDA, Breast cancer, Disease, Pharmaceutical industry, Dalhousie
WATERTOWN, Mass., June 20, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced the appointment of Leonard (Len) Reyno, M.D., as chief medical officer, effective July 10, 2023. Dr. Reyno is a seasoned biotech executive with nearly 30 years of clinical development experience, spanning first-in-human studies to Phase IV clinical trials. At C4T, Dr. Reyno will be responsible for driving C4T’s clinical strategy to advance its promising pipeline of degrader therapies.
Key Points:
- Dr. Reyno is a seasoned biotech executive with nearly 30 years of clinical development experience, spanning first-in-human studies to Phase IV clinical trials.
- At C4T, Dr. Reyno will be responsible for driving C4T’s clinical strategy to advance its promising pipeline of degrader therapies.
- “We look forward to leveraging Len’s track record of advancing novel oncology therapeutics to patients, deep strategic and operational experience in clinical development and organizational leadership capabilities,” said Andrew Hirsch, president and chief executive officer of C4 Therapeutics.
- Prior to Pionyr, he was executive vice president and chief medical officer at ORIC Pharmaceuticals, leading their first product candidate into human trials.